Cardiology

The phase 2 KARDIA-1 study reports a single dose of zilebesiran safely reduced systolic blood pressure in people with mild-to-moderate hypertension for up to 6 months.

Results of the ARTESIA trial suggest apixaban lowered stroke risk by 37% in subclinical atrial fibrillation versus aspirin, but increased major bleeding risk.

Presented at AHA 2023, the topline analysis of the phase 2 AZALEA-TIMI 71 trial showed abelacimab significantly reduced bleeding in people with Afib at risk of stroke, compared with rivaroxaban.

Brendon Neuen, MBBS, PhD, discusses the results of a study he presented at AHA 2023 estimating the lifetime benefit of combination therapy in patients with type 2 diabetes and albuminuria.

New analyses from the phase 3 MAESTRO-NASH support the oral daily drug's benefit for cardiovascular and hormonal outcomes over 1 year.

ORBITA-2 trial: Percutaneous coronary intervention improved chest pain and quality of life vs. placebo in stable angina patients.

In the phase 2 ReVeRA trial, etripamil nasal spray provided a marked reduction in ventricular rates among patients with atrial fibrillation and rapid ventricular rates.

The MINT trial, which included 3504 patients with acute MI and anemia, shows a trend favoring liberal transfusion, indicating a potential for improved outcomes.

In this episode, hosts take a deep dive into the study’s results, including secondary endpoints, and what it means for the care of patients with overweight or obesity and preexisting cardiovascular disease in real-world settings.

Full data from the SELECT trial offer insight into the 20% relative risk reduction associated with use of semaglutide 2.4 mg in patients with overweight or obesity and preexisting cardiovascular disease at AHA 2023.

Marc Bonaca, MD, discusses an AHA 2023 study he led examining trends in discordance between LVEF and ICD-10 codes used in heart failure hospitalizations.

Paul Ridker, MD, MPH, discusses the evolving recognition of the role inflammation plays in driving cardiovascular risk among patients with atherosclerosis.

On November 7, 2023, Recor Medical announced the FDA approval of their Paradise Ultrasound Renal Denervation system for the treatment of hypertension.

Check out perspective from a pair of ASN Kidney Week 2023 interviews with leading trialists discussing the evolution of cardiovascular-kidney-metabolic syndrome and how pharmacotherapy has propelled the growing recognition.

John W. Ostrominski, MD, describes the prevalence and overlap of cardiac, renal, and metabolic conditions in US adults over a 20-year period.

This case report from Brady Pregerson, MD, features a woman in her mid-60s presenting to the ER with generalized weakness and dyspnea. Can you determine the correct diagnosis?

Announced by Milestone Pharmaceuticals on October 24, 2023, the New Drug Application includes positive results on etripamil from the pivotal phase 3 RAPID trial.

Dhiren Patel, PharmD, and Bob Busch, MD, interview Fatima Cody Stanford, MD, MPH, MPA, an obesity medicine specialist, to examine the cardiovascular (CV) impact of obesity and delve into the potential benefits of newer weight loss medications in mitigating CV risk and heart failure.

The first-of-its-kind Aurora EV-ICD system offers a single-device, single procedure with a lead placed outside of the heart and veins.

This case report from Brady Pregerson, MD, features a woman in her mid-80s with a history of ASCVD admitted for intermittent chest pain. Check out the ECG and determine the correct diagnosis!

A highlight of different sessions, presentations, and conversations focused on trends and impact of disparities in women's heart health at HFSA 2023.

Alex Hajduczok, MD, provides perspective on the new GUIDE-HF trial data presented at HFSA 2023.

Dhiren Patel, PharmD, and Bob Busch, MD, interview Fatima Cody Stanford, MD, MPH, MPA, an obesity medicine specialist, to examine the cardiovascular (CV) impact of obesity and delve into the potential benefits of newer weight loss medications in mitigating CV risk and heart failure.

A group of 9 experts in heart failure, ranging from leading trialists to early career clinicians, provide perspective on what they see as the biggest news in heart failure from 2023.

Ahmad Masri, MD, MS, discusses long-term data from the open-label extension period of the phase 2 AG10-201 trial examining acoramidis in patients with ATTR-CM.